Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).
Cardiovascular disease is the leading cause of death in Fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3
Think Fabry, think renal involvement that may present early in life and could go undetected.
Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2
A podcast series designed by cardiologists, for cardiologists and other healthcare professionals.
The Building Care webinar series is designed to deepen your understanding of the critical role a patient-centered, multidisciplinary approach plays in managing Fabry disease.
Du er i ferd med å forlate campus.sanofi/no. Sanofi er ikke ansvarlig for innholdet på dette eksterne Nettstedet.
Denne nettsiden inneholder informasjon som er kun for helsepersonell som lege, tannlege, offentlig godkjent sykepleier, farmasøyt, optiker, tannpleier, samt studenter i disse fag.